Staar Surgical Co. Stock
€38.28
Your prediction
Staar Surgical Co. Stock
Pros and Cons of Staar Surgical Co. in the next few years
Pros
Cons
Performance of Staar Surgical Co. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Staar Surgical Co. | 1.410% | -1.922% | -13.433% | -29.190% | 31.864% | -68.166% | - |
Orasure Tech | -3.180% | -5.752% | -14.800% | -5.752% | -42.819% | -45.427% | -41.708% |
scPharmaceuticals | 7.020% | 11.585% | -12.857% | -61.270% | -36.348% | -20.087% | - |
SI-BONE Inc | -0.810% | 0.820% | -8.209% | -46.522% | -35.263% | -49.590% | - |
Comments
News
STAAR Surgical Reports First Quarter 2024 Results
STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical to Report First Quarter Results on May 7, 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today